Cyclooxygenase-2 regulates granulocyte-macrophage colony-stimulating factor, but not interleukin-8, production by human vascular cells role of cAMP

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 3, 2000, Pages 677-682

  Stanford, Salome J ^a   Pepper, John R ^a   Mitchell, Jane A ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aspirin; Atherosclerosis; Inflammation; Interleukin 8; Neutrophils

Indexed keywords

BUCLADESINE; CYCLIC AMP; CYCLOOXYGENASE 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 8;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR SMOOTH MUSCLE;

EID: 0034103176     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.3.677     Document Type: Article

References (40)

1. Colditz I, Zwahlen R, Dewald B, Baggiolini M. In vivo inflammatory activity of neutrophil-activating factor, a novel chemotactic peptide derived from human monocytes. Am J Pathol. 1989;134:755-760.
2. Metcalf D. The molecular biology of the granulocyte-macrophage colony-stimulating factor. Blood. 1986;67:257-267.
3. Lopez AF, Williamson DJ, Gamble JR, Begley CG, Harlan JM, Klebanoff SJ, Waltersdorph A, Wong G, Clark SC, Vadas MA. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression and survival. J Clin Invest. 1986;78:1220-1228.
4. Jourdan KB, Mitchell JA, Evans TW. Release of isoprostanes by human pulmonary artery in organ culture: a cyclo-oxygenase and nitric oxide dependent pathway. Biochem Biophys Res Commun. 1997;233:668-672.
5. Bishop-Bailey D, Pepper JR, Haddad EB, Newton R, Larkin SW, Mitchell JA. Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery. Arterioscler Thromb Vasc Biol. 1997;17: 1644-1648.
6. Bishop-Bailey D, Pepper JR, Larkin SW, Evans TW, Mitchell JA. Differential induction of cyclo-oxygenase-2 in human arterial and venous smooth muscle cells: role of endogenous prostanoids. Br J Pharmacol. 1997;122:19P. Abstract.
7. Wang JM, Sica A, Peri G, Walter S, Padura IM, Libby P, Ceska M, Lindley I, Colotta F, Mantovani A. Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb. 1991;11:1166-1174.
8. Filonzi EL, Zoellner H, Stanton H, Hamilton JA. Cytokine regulation of granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor production in human arterial smooth muscle cells. Atherosclerosis. 1993;99:241-252.
9. Saunders MA, Mitchell JA, Seldon PM, Yacoub MH, Barnes PJ, Giembycz MA, Belvisi MG. Release of granulocyte-macrophage colony stimulating factor by human cultured airway smooth muscle cells: suppression by dexamethasone. Br J Pharmacol. 1997;120:545-546.
10. Mitchell JA, Akarasereenonl P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993; 90:11693-11697.
11. Bishop-Bailey D, Pepper JR, Larkin SW, Mitchell JA. Differential induction of cyclo-oxygenase-2 in human arterial and venous smooth muscle: role of endogenous prostanoids. Arterioscler Thromb Vasc Biol. 1998;18:1655-1661.
12. Kuehl FA Jr, Egan RW. Prostaglandins, arachidonic acid, and inflammation. Science. 1980;210:978-984.
13. Palmblad J. The role of granulocytes in inflammation. Scand J Rheumatol. 1984;13:163-172.
14. Fantone JC, Ward PA. Polymorphonuclear leukocyte-mediated cell and tissue injury: oxygen metabolites and their relations to human disease. Hum Pathol. 1985;16:973-978.
15. Ferrante A, Kowanko IC, Bates EJ. Mechanisms of host tissue damage by cytokine-activated neutrophils. Immunol Ser. 1992;57:499-521.
16. Smith JA. Neutrophils, host defence, and inflammation: a double-edged sword. J Leukoc Biol. 1994;56:672-686.
17. Patil RR, Borch RF. Granulocyte-macrophage colony-stimulating factor expression by human fibroblasts is both upregulated and subsequently downregulated by interleukin-1. Blood. 1995;85:80-86.
18. 2 enhances interleukin-8 (IL-8) and IL-6 but inhibits GM-CSF production by IL-1 stimulated human synovial fibroblasts in vitro. J Rheumatol. 1996;23: 862-868.
19. Weissmann G, Korchak H, Ludewig R, Edelson H, Haines K, Levin RI, Herman R, Rider L, Kimmel S, Abramson S. Non-steroidal antiinflammatory drugs: how do they work? Eur J Rheumatol Inflamm. 1987;8:6-17.
20. Abramson SB, Cherksey B, Gude D, Leszczynska-Piziak J, Philips MR, Blau L, Weissmann G. Nonsteroidal antiinflammatory drugs exert differential effects on neutrophil function and plasma membrane viscosity: studies in human neutrophils and liposomes. Inflammation. 1990;14: 11-30.
21. Cronstein BN, Van de Stouwe M, Druska L, Levin RI, Weissmann G. Non-steroidal antiinflammatory agents inhibit stimulated neutrophil adhesion to endothelium: adenosine dependent and independent mechanisms. Inflammation. 1994;18:323-335.
22. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A. 1991;88:2692-2696.
23. Simon HU, Yousefi S, Weber M, Simon D, Holzer C, Hartung K, Blaser K. Human peripheral blood eosinophils express and release interleukin-8. Int Arch Allergy Immunol. 1995;107:124-126.
24. Mitchell JA, Larkin SW, Williams TJ. Cyclooxygenase-2: regulation and relevance in inflammation. Biochem Pharmacol. 1995;50:1535-1542.
25. Sano H, Hla T, Maier JA, Crofford LJ, Case JP, Maciag T, Wilder RL. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest. 1992;89:97-108.
26. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, Hill RG, Li CS, Mancini J, Penneton M. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745.337: a novel nonsteroidal antiinflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther. 1995;274: 1531-1537.
27. Dong YJ, Jones RL, Wilson NH. Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues. Br J Pharmacol. 1986;87:97-107.
28. 2 analogue, cicaprost (ZK 96480), in different animal species and in man. Biomed Biochim Acta. 1988;47:S45-S47.
29. Bug G, Aman J, Huber C, Peschel C, Derigs HG. cAMP analogues downregulate the expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) in human bone marrow stromal cells in vitro. Mediators Inflamm. 1998;7:195-199.
30. Best LC, Martin TJ, Russell RG, Preston FE. Prostacyclin increases cyclic AMP levels and adenylyl cyclase activity in platelets. Nature. 1977;267:850-852.
31. Schror K, Link HB, Rosen R, Klaus W, Rosen P. Prostacyclin-induced coronary vasodilatation: interactions with adenosine, cyclic AMP and energy charge in the rat heart in vitro. Eur J Pharmacol. 1980;64: 341-348.
32. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663-665.
33. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987;92:639-646.
34. Sneddon JM, Vane JR. Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci U S A. 1988;85:2800-2804.
35. Willis AL, Smith DL, Vigo C. Suppression of principal atherosclerotic mechanisms by prostacyclins and other eicosanoids. Prog Lipid Res. 1986;25:645-666.
36. Sinzinger H, Fitscha P, Kritz H. Antimitotic actions of vasodilatory prostaglandins: clinical aspects. Agents Actions Suppl. 1997;48:92-106.
37. Cockerill GW, Saklatvala J, Ridley SH, Yarwood H, Miller NE, Oral B, Nithyanathan S, Taylor G, Haskard DO. High-density lipoproteins differentially modulated cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler Thromb Vasc Biol. 1999;19:910-917.
38. Abdalla DS, Campa A, Monteiro HP. Low density lipoprotein oxidation by stimulated neutrophils and ferritin. Atherosclerosis. 1992;97:149-159.
39. Cogny A, Paul JL, Atger V, Soni T, Moatti N. Structural changes of high-density-lipoprotein apolipoproteins following incubation with human polymorphonuclear cells. Eur J Biochem. 1994;222:965-973.
40. Couderc R, Bonneau C, Tissot M, Bailleul S, Roch-Arveiller M, Giroud JP. Effects of plasma lipoproteins on the production of superoxide anion by human polymorphonuclear leukocytes in vitro. Biofactors. 1997;6: 157-163.